News | Heart Valve Technology | November 09, 2021

Intermediate-risk Patients Have Similar Five-year Outcomes With Transcatheter or Surgical Aortic Valve Replacement

Five-year data from the SURTAVI trial found no difference in all-cause mortality or stroke between TAVR and SAVR patients

TAVR CT image reconstruction of an implanted Medtronic CoreValve. #TCT21 #TCT #TAVR #SURTAVI

TAVR CT image reconstruction of an implanted Medtronic CoreValve.


November 9, 2021 — New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality or stroke between patients at intermediate surgical risk who had transcatheter aortic valve replacement (TAVR) or surgery. Although there were initially more reinterventions after TAVR, the rates were similar after two years and key clinical endpoints were also similar.

Findings were reported today at TCT 2021, the 33rd annual scientific symposium of the Cardiovascular Research Foundation (CRF).

“Longer-term outcomes data from the SURTAVI randomized trial comparing early-generation TAVR to open-heart surgery are similar and encouraging for TAVR in younger, healthier patients with aortic stenosis,” said Nicolas M. Van Mieghem, M.D., Ph.D., professor of interventional cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands.

Early randomized TAVR trials enrolled patients at high operative risk with reserved long-term prognosis.

TAVR with balloon-expandable valves in intermediate-risk patients at five years was associated with higher rates of readmission and similar hemodynamics compared to surgery. Limited long-term data exists comparing surgery with self-expanding supra-annular TAVR.

A total of 1,660 intermediate-risk patients (risk of operative mortality ≥3% to <15%) underwent attempted implant of a transcatheter aortic valve (n=864) or a surgical valve (n=796) at 87 centers in Canada, Europe and the United States. Patients were stratified by investigational site and need for revascularization. Concomitant or staged PCI in the TAVR arm or coronary bypass graft in the surgical arm was performed as indicated.

The primary endpoint, consisting of the composite of death or disabling stroke at five years, were similar in both groups with 31.3% for TAVR and 30.8% for surgery (HR 1.02, 95% CI .085-1.22, p=0.85). All-cause mortality had similar rates and disabling stroke was 4.1% for TAVR compared to 5.8% for surgery (HR 0.69, 95% CI 0.43-1.10, p=0.12). At two years, reinterventions were higher with TAVR (2.5% versus 0.5%, log-rank p=0.002). However, at years three through five, the rates were similar. At five years, the reintervention rate for TAVR was 1.0% compared to 1.3% compared with surgery (log-rank p=0.60).

Core lab-assessed valve regurgitation showed that surgery patients had significantly less ≥ mild aortic regurgitation or paravalvular leak than TAVR at one, two and five-year follow-ups (all p < 0.001). Kansas City Cardiomyopathy Questionnaire summary scores were higher for TAVR patients at one year. However, the scores were similar at each additional follow up through five years. New York Heart Association Class was also similar between both groups at each follow up. In addition, forward-flow hemodynamics were significantly better with TAVR.

The study was funded by Medtronic. He reported the following disclosures: research grants from Abbott Vascular, Boston Scientific, Edwards Lifesciences, Medtronic, Daiichi Sankyo, Abiomed, PulseCath BV and Pie Medical.

Links to All the TCT 2021 Late-Breaking Clinical Trials

More structural heart technology news

 

Related Content

Feature | TCT

November 10, 2021 — There were nine late-breaking trials and 13 late-breaking science presentations at the 2021 ...

Home November 10, 2021
Home
Feature | TCT | Dave Fornell, Editor

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

Home October 29, 2020
Home
Feature | TCT

October 15, 2020 — The late-breaking studies are one of the hallmarks of the annual Transcatheter Cardiovascular ...

Home October 15, 2020
Home
News | TCT

October 14, 2020 — The American College of Cardiology (ACC) and the Cardiovascular Research Foundation (CRF) are ...

Home October 14, 2020
Home
Videos | TCT

With COVID-19 forcing all medical conferences to go virtual in 2020, Juan F. Granada, M.D., CEO of the Cardiovascular ...

Home August 01, 2020
Home
Feature | TCT | Dave Fornell, Editor

The latest in interventional cardiology clinical data and new device technologies were highlighted at the annual ...

Home November 04, 2019
Home
Feature | TCT

October 10, 2019 — Here are the Cardiovascular Research Foundation (CRF) 12 late-breaking trials and 16 late-breaking ...

Home October 11, 2019
Home
Videos | TCT

Chandan Devireddy, M.D., offers insights about what he saw as the top take aways from the 2019 Transcatheter ...

Home October 04, 2019
Home
Videos | TCT

DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the expo ...

Home October 03, 2018
Home
Feature | TCT

October 4, 2018 – The Cardiovascular Research Foundation (CRF) had 15 late-breaking trials and 12 late-breaking clinical ...

Home September 21, 2018
Home
Subscribe Now